TQB3473

· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for TQB3473, covering 2025-05-20 to 2025-07-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults [Phase 2]

See pricing